Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors

Tamoxifen is the treatment of choice in estrogen receptor alpha breast cancer patients that are eligible for adjuvant endocrine therapy. However, ∼50% of ERα-positive tumors exhibit intrinsic or rapidly acquire resistance to endocrine treatment. Unfortunately, prediction of de novo resistance to endocrine therapy and/or assessment of relapse likelihood remain difficult. While several mechanisms regulating the acquisition and the maintenance of endocrine resistance have been reported, there are several aspects of this phenomenon that need to be further elucidated.

Source: Molecular Oncology - June 4, 2015 Category: Cancer & Oncology Authors: George Notas, Vassiliki Pelekanou, Marilena Kampa, Konstantinos Alexakis, Stelios Sfakianakis, Aggelos Laliotis, John Askoxilakis, Eleftheria Tsentelierou, Maria Tzardi, Andreas Tsapis, Elias Castanas Source Type: research